LY 210825

a recombinant tissue-type plasminogen activator, which contains the kringle-2 & serine protease functional domains of native tissue-type plasminogen activator; has longer plasma half life than recombinant tissue-type plasminogen activator

Also Known As:

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Thrombosis (Thrombus) 09/01/1990 - "In a canine model of coronary artery thrombosis, LY210825 was a more effective thrombolytic agent than was rt-PA." 09/01/1990 - "Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis."
2.	Hemorrhage 01/01/1992 - "In addition, LY210825 spared plasma fibrinogen, plasminogen and alpha-2 antiplasmin and therefore, could potentially minimize the risk of bleeding complications."

Related Drugs and Biologics

1.	Plasminogen Activators (Plasminogen Activator)
2.	Tissue Plasminogen Activator (Alteplase)
3.	Plasminogen
4.	Fibrinolytic Agents (Antithrombotic Agents)
5.	Fibrinogen (Factor I)
6.	alpha-2-Antiplasmin (alpha 2 Antiplasmin)